Alnylam CFO sells 2,468 shares for tax withholding

ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported selling 2,468 shares of common stock on March 4, 2026 in a series of open-market sales.

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported selling 2,468 shares of common stock on March 4, 2026 in a series of open-market sales. Reported prices for these transactions include $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67 per share.

According to a footnote, these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations upon the vesting of restricted stock units. After these sales, Poulton directly owned 62,028 shares and indirectly held 57 shares of ALNY common stock through a managed account.

Insider Trade Summary

Net Seller: 2,468 shares

Net Sell 9 txns

Insider Poulton Jeffrey V.

Role EVP, Chief Financial Officer

Sold 2,468 shs ($797K)

Type	Security	Shares	Price	Value
Sale	Common Stock	114	$319.03	$36K
Sale	Common Stock	109	$320.01	$35K
Sale	Common Stock	230	$320.81	$74K
Sale	Common Stock	309	$321.82	$99K
Sale	Common Stock	374	$323.01	$121K
Sale	Common Stock	818	$323.84	$265K
Sale	Common Stock	291	$324.88	$95K
Sale	Common Stock	223	$325.67	$73K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 61,805 shares (Direct); Common Stock — 57 shares (Indirect, by Managed Account)

Footnotes (10)

1. F1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
2. F2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. F4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. F5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. F6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7. F7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
8. F8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
9. F9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
10. F10. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALNY EVP and CFO Jeffrey Poulton report on his latest Form 4 for ALNY?

Jeffrey V. Poulton, EVP and chief financial officer of ALNYLAM PHARMACEUTICALS (ALNY), reported automatic open-market sales of 2,468 common shares on March 4, 2026. These transactions were used to cover minimum statutory tax withholding tied to restricted stock unit vesting.

How many ALNY shares did CFO Jeffrey Poulton sell and at what prices?

Jeffrey Poulton reported selling 2,468 ALNY common shares in multiple open-market trades. Reported transaction prices included $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67 per share, reflecting a range of executions on the same day.

Were Jeffrey Poulton’s ALNY share sales discretionary or related to tax withholding?

The sales were not purely discretionary. A footnote states the 2,468 shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations arising from the vesting of restricted stock units granted to Jeffrey Poulton.

How many ALNY shares does Jeffrey Poulton hold after the reported Form 4 transactions?

Following the reported transactions, Jeffrey Poulton directly held 62,028 shares of ALNY common stock. He also indirectly owned 57 shares through a managed account, which the footnotes describe as reflecting stock acquired via the company’s 401(k) matching contribution program.

What role does Jeffrey V. Poulton hold at ALNYLAM PHARMACEUTICALS?

Jeffrey V. Poulton serves as executive vice president and chief financial officer of ALNYLAM PHARMACEUTICALS. His Form 4 filing details his personal holdings in ALNY common stock, including direct ownership of 62,028 shares and additional indirect holdings through a managed account structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poulton Jeffrey V.

(Last) (First) (Middle)

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		114	D	$319.03(2)	64,159	D
Common Stock	03/04/2026		S(1)		109	D	$320.01(3)	64,050	D
Common Stock	03/04/2026		S(1)		230	D	$320.81(4)	63,820	D
Common Stock	03/04/2026		S(1)		309	D	$321.82(5)	63,511	D
Common Stock	03/04/2026		S(1)		374	D	$323.01(6)	63,137	D
Common Stock	03/04/2026		S(1)		818	D	$323.84(7)	62,319	D
Common Stock	03/04/2026		S(1)		291	D	$324.88(8)	62,028	D
Common Stock	03/04/2026		S(1)		223	D	$325.67(9)	61,805	D
Common Stock								57	I	by Managed Account(10)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

10. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

	By: Brett Budzinski, Attorney-in-Fact For: Jeffrey V. Poulton	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.